Associations between proteasomal activator PA28γ and outcome of oral squamous cell carcinoma: Evidence from cohort studies and functional analyses

EBioMedicine

Volumn 2, Issue 8, 2015, Pages 851-858

  Li, Jing ^a   Feng, Xiaodong ^a   Sun, Chongkun ^a   Zeng, Xin ^a   Xie, Liang ^a   Xu, Hao ^a,b   Li, Taiwen ^a   Wang, Ruinan ^a   Xu, Xiaoping ^a   Zhou, Xikun ^c   Zhou, Min ^a   Zhou, Yu ^a   Dan, Hongxia ^a   Wang, Zhiyong ^a   Ji, Ning ^a   Deng, Peng ^a   Liao, Ga ^a   Geng, Ning ^a   Wang, Yun ^a   Zhang, Dunfang ^a   Lin, Yunfeng ^a   Ye, Ling ^a   Liang, Xinhua ^a   Li, Longjiang ^a   Luo, Gang ^d   Jiang, Lu ^a   Wang, Zhi ^a   Chen, Qianming ^a   more..

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

^d SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Carcinogenesis; OSCC; PA28 ; Prognosis

Indexed keywords

MESSENGER RNA; PROTEASOME ACTIVATOR PA28 GAMMA; PROTEIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; AUTOANTIGEN; KI ANTIGEN; PROTEASOME;

ADULT; AGED; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL LINE; CANCER MORTALITY; CANCER PROGNOSIS; CAPILLARY DENSITY; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; MTT ASSAY; NONHUMAN; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUNEL ASSAY; VERY ELDERLY; WESTERN BLOTTING; ANIMAL; BIOLOGICAL MODEL; BIOSYNTHESIS; CLINICAL TRIAL; ENZYMOLOGY; GENE EXPRESSION REGULATION; MORTALITY; MOUTH TUMOR; MULTICENTER STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

AGED; ANIMALS; AUTOANTIGENS; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MIDDLE AGED; MODELS, BIOLOGICAL; MOUTH NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; SURVIVAL RATE;

EID: 84951573784     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.07.004     Document Type: Article

References (34)

1. Ali A., Wang Z., Fu J., et al. Differential regulation of the REGgamma-proteasome pathway by p53/TGF-beta signalling and mutant p53 in cancer cells. Nat. Commun. 2013, 4:2667.
2. Araya R., Takahashi R., Nomura Y. Yeast two-hybrid screening using constitutive-active caspase-7 as bait in the identification of PA28gamma as an effector caspase substrate. Cell Death Differ. 2002, 9(3):322-328.
3. Barton L.F., Runnels H.A., Schell T.D., et al. Immune defects in 28-kDa proteasome activator gamma-deficient mice. J. Immunol. 2004, 172(6):3948-3954.
4. Cancer Genome Atlas N Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015, 517(7536):576-582.
5. Chen X., Barton L.F., Chi Y., Clurman B.E., Roberts J.M. Ubiquitin-independent degradation of cell-cycle inhibitors by the REGgamma proteasome. Mol. Cell 2007, 26(6):843-852.
6. Choi S., Myers J.N. Molecular pathogenesis of oral squamous cell carcinoma: implications for therapy. J. Dent. Res. 2008, 87(1):14-32.
7. Chung C.H., Zhang Q., Kong C.S., et al. p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J. Clin. Oncol. 2014, 32(35):3930-3938.
8. Dong S., Jia C., Zhang S., et al. The REGgamma proteasome regulates hepatic lipid metabolism through inhibition of autophagy. Cell Metab. 2013, 18(3):380-391.
9. He J., Cui L., Zeng Y., et al. REGgamma is associated with multiple oncogenic pathways in human cancers. BMC Cancer 2012, 12:75.
10. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61(2):69-90.
11. Kilkenny C., Browne W.J., Cuthill I.C., Emerson M., Altman D.G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010, 8(6):e1000412.
12. Kloetzel P.M., Ossendorp F. Proteasome and peptidase function in MHC-class-I-mediated antigen presentation. Curr. Opin. Immunol. 2004, 16(1):76-81.
13. Li X., Amazit L., Long W., Lonard D.M., Monaco J.J., O'Malley B.W. Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. Mol. Cell 2007, 26(6):831-842.
14. Li J., Tian T., Wang X., Li F., Ren G. Expression and clinical significance of REGγ in gastric cancer tissue and variously differentiated gastric cancer cell lines. Clin. Oncol. Cancer Res. 2009, 6(3):208-213.
15. Li L., Zhao D., Wei H., et al. REGgamma deficiency promotes premature aging via the casein kinase 1 pathway. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(27):11005-11010.
16. Liu J., Yu G., Zhao Y., et al. REGgamma modulates p53 activity by regulating its cellular localization. J. Cell Sci. 2010, 123(Pt 23):4076-4084.
17. Liu S., Lai L., Zuo Q., et al. PKA turnover by the REGgamma-proteasome modulates FoxO1 cellular activity and VEGF-induced angiogenesis. J. Mol. Cell. Cardiol. 2014, 72:28-38.
18. Magni M., Ruscica V., Buscemi G., et al. Chk2 and REGgamma-dependent DBC1 regulation in DNA damage induced apoptosis. Nucleic Acids Res. 2014, 42(21):13150-13160.
19. Panzarella V., Pizzo G., Calvino F., Compilato D., Colella G., Campisi G. Diagnostic delay in oral squamous cell carcinoma: the role of cognitive and psychological variables. Int. J. Oral Sci. 2014, 6(1):39-45.
20. Principe S., Hui A.B., Bruce J., Sinha A., Liu F.F., Kislinger T. Tumor-derived exosomes and microvesicles in head and neck cancer: implications for tumor biology and biomarker discovery. Proteomics 2013, 13(10-11):1608-1623.
21. Ratajczak-Wrona W., Jablonska E., Antonowicz B., Dziemianczyk D., Grabowska S.Z. Levels of biological markers of nitric oxide in serum of patients with squamous cell carcinoma of the oral cavity. Int. J. Oral Sci. 2013, 5(3):141-145.
22. Rechsteiner M., Hill C.P. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol. 2005, 15(1):27-33.
23. Rechsteiner M., Realini C., Ustrell V. The proteasome activator 11S REG (PA28) and class I antigen presentation. Biochem. J. 2000, 345(Pt 1):1-15.
24. Rivett A.J., Hearn A.R. Proteasome function in antigen presentation: immunoproteasome complexes, peptide production, and interactions with viral proteins. Curr. Protein Pept. Sci. 2004, 5(3):153-161.
25. Roessler M., Rollinger W., Mantovani-Endl L., et al. Identification of PSME3 as a novel serum tumor marker for colorectal cancer by combining two-dimensional polyacrylamide gel electrophoresis with a strictly mass spectrometry-based approach for data analysis. Mol. Cell. Proteomics 2006, 5(11):2092-2101.
26. Shi Y., Luo X., Li P., et al. miR-7-5p suppresses cell proliferation and induces apoptosis of breast cancer cells mainly by targeting REGgamma. Cancer Lett. 2015, 358(1):27-36.
27. Wan Z.X., Yuan D.M., Zhuo Y.M., et al. The proteasome activator PA28gamma, a negative regulator of p53, is transcriptionally up-regulated by p53. Int. J. Mol. Sci. 2014, 15(2):2573-2584.
28. Wang Z., Jiang L., Huang C., et al. Comparative proteomics approach to screening of potential diagnostic and therapeutic targets for oral squamous cell carcinoma. Mol. Cell. Proteomics 2008, 7(9):1639-1650.
29. Wang Z., Feng X., Liu X., et al. Involvement of potential pathways in malignant transformation from oral leukoplakia to oral squamous cell carcinoma revealed by proteomic analysis. BMC Genomics 2009, 10:383.
30. Wang X., Tu S., Tan J., et al. REG gamma: a potential marker in breast cancer and effect on cell cycle and proliferation of breast cancer cell. Med. Oncol. 2011, 28(1):31-41.
31. Wang H., Bao W., Jiang F., et al. Mutant p53 (p53-R248Q) functions as an oncogene in promoting endometrial cancer by up-regulating REGgamma. Cancer Lett. 2015, 360(2):269-279.
32. Yan Q., Sharma-Kuinkel B.K., Deshmukh H., et al. Dusp3 and Psme3 are associated with murine susceptibility to Staphylococcus aureus infection and human sepsis. PLoS Pathog. 2014, 10(6):e1004149.
33. Ying H., Furuya F., Zhao L., et al. Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J. Clin. Invest. 2006, 116(11):2972-2984.
34. Zhang Z., Zhang R. Proteasome activator PA28 gamma regulates p53 by enhancing its MDM2-mediated degradation. EMBO J. 2008, 27(6):852-864.